

Recombinant Human IGF-BP5

Catalog # PBG10174

Specification

Recombinant Human IGF-BP5 - Product Information

Recombinant Human IGF-BP5 - Additional Information

Description

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Data shows that IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.

BiologicalActivity

The ED₅₀ was determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is \leq 0.3 µg/ml in the presence of 15 ng/ml of human IGF-II.

Authenticity

Verified by N-terminal and Mass Spectrometry analyses (when applicable).

Endotoxin

Endotoxin level is $<0.1 \text{ ng}/\mu\text{g}$ of protein ($<1\text{EU}/\mu\text{g}$).

Protein Content

Verified by UV Spectroscopy and/or SDS-PAGE gel.

Storage

-20°C

Precautions

Recombinant Human IGF-BP5 is for research use only and not for use in diagnostic or therapeutic procedures.

Recombinant Human IGF-BP5 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence





- Immunoprecipitation
- Flow Cytomety
 Cell Culture

Recombinant Human IGF-BP5 - Images